Metagenomi Therapeutics, Inc. (MGX) Stock Price & Analysis
Metagenomi Therapeutics, Inc. (MGX) closed at USD 0.85 on Thursday, October 15, 2026, down 1.86% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.86; the Oct 15, 2026 session ranged USD 0.84–0.88 on volume of 291,419 shares. Market capitalization is $31.93M, with a 52-week range of USD 0.84–3.4 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MGX.md
Key facts (MGX)
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 7 (range 5–9).
- Total return with dividends: 1Y -74.6% vs S&P 500 +18.1%; 5Y -91.8% vs S&P 500 +85.1%.
Analysts (MGX)
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 7 (low 5, high 9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | Wells Fargo | Target lowered | Overweight | $9 → $7 |
| 2026-07-07 | Chardan Capital | Target lowered | Buy | $7 → $5 |
Total return (dividends reinvested) (MGX)
| 1Y (from 2025-10-16) | 5Y (from 2024-02-05) | |
|---|---|---|
| Total return | -74.6% | -91.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -74.7% | -60.5% |
| Volatility (annualized) | 57.6% | 80.6% |
| Max drawdown | -74.8% (Oct 2025→Oct 2026) | -93.1% (Feb 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 0.85 |
|---|---|
| Change | ▼ 1.86% (down) |
| Previous Close | USD 0.86 |
| Open | USD 0.86 |
| Day Range | USD 0.84 – 0.88 |
| 52-Week Range | USD 0.84 – 3.4 |
| Volume | 291,419 shares |
| Market Cap | $31.93M |
| Exchange | NMS |
Technical Analysis (MGX)
Nexqual's technical model rates MGX "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.22 (oversold) |
| vs SMA50 | Below (USD 1.14) |
| MACD | -0.07 (negative) |
Analyst Ratings (MGX)
Wall Street analysts rate MGX "Buy" based on 5 analysts, with a mean price target of USD 7 (range USD 5–9), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7 |
| High Target | USD 9 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (MGX)
| EPS Estimate | USD -0.62 |
|---|---|
| Revenue Estimate | $2.06M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.73 vs est -0.52 ▼ miss |
| 2026-03-31 | USD -0.61 vs est -0.55 ▼ miss |
| 2025-12-31 | USD -0.6 vs est -0.59 ▼ miss |
| 2025-09-30 | USD -0.55 vs est -0.53 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (MGX)
| Total Revenue | $13.56M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +11195.72% |
| Profit Margin | +0.00% |
| ROE | -60.61% |
| Debt / Equity | 0.34 |
| Current Ratio | 4.5 |
| Total Cash | $120.66M |
| Total Debt | $37.72M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (MGX)
Nexqual rates Metagenomi Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Critical — Revenue -52% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $121M cash vs $38M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$85M (TTM) |
| Efficiency | Critical — ROE -61%, ROA -28.2% |
Ownership (MGX)
| Insider Ownership | +19.02% |
|---|---|
| Institutional Ownership | +18.53% |
| Shares Outstanding | 37.78M |
| Float | 25.54M |
| Short % of Float | +4.15% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (MGX)
Metagenomi Therapeutics, Inc. is led by Jian Irish (age 61), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO, President & Director | Jian Irish (age 61) |
|---|---|
| Chief Financial Officer | Pamela M. Wapnick (age 59) |
| Senior Vice President of Research | Alan Brooks (age 59) |
| Senior Vice President of Business Development | Nikhil Bhide |
Major Backers & Investors (MGX)
Notable institutional backers of Metagenomi Therapeutics, Inc. include Renaissance Technologies, Catalio Capital Management, LP , Peapod Lane Capital LLC , according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 1.97% |
| Catalio Capital Management, LP | 1.4% |
| Peapod Lane Capital LLC | 1.39% |
| Two Sigma Investments, LP | 1.36% |
| Bridgeway Capital Management, LLC | 1.06% |
| Wells Fargo & Company | 1% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.71% |
| BlackRock | 0.93% |
| Geode Capital | 0.76% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt